Functional analyses have revealed that both human and murine pDCs can activate CD8+ T cells, leading to their differentiation into cytolytic and IFN-γ-producing effector T cells, thereby promoting tumor regression in vivo. This evidence concerns the gene CD8A and neoplasm.